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LETTER TO THE EDITOR
TAF1 as the Most Plausible Disease Gene
for XDP/DYT3
To the Editor: We address the concerns of Dr. Mu¨ller and
his colleagues1(in this issue) regarding our recent article in the
Journal.2 Previously, Mu¨ller et al. reported that ﬁve disease-
speciﬁc single-nucleotide changes (DSCs) in a “multiple
transcript system” (MTS) were associated with XDP (MIM
#314250).3 Our article was the ﬁrst to report TAF1 (MIM
*313650) as the most plausible disease gene,2 and it is
regrettable that no one has succeeded in conﬁrming MTS
transcripts by any standard technologies, such as northern
blot, to provide the information on length and abundance
of the transcripts. Therefore, the term “TAF1/DYT3 mul-
tiple transcript system” is ambiguous andmisleading.TAF1
and MTS are different genes that have distinct functions,
although some alternative splicing exons of TAF1 are
shared with some MTS transcripts. In particular, we claim
that the neuron-speciﬁc isoform of TAF1 was discovered
by us.2
The following are the responses to the points raised by
Mu¨ller et al.1
1. As listed in our table 5, the splicing variant of MTS
that includes exons 32′ and 34′ was never detected by our
TaqMan assay.2 Our results from long RT-PCR analysis con-
sistently show that exons 3 and 4 may be just an addi-
tional part of the 3′ UTR of TAF1, rather than part of MTS
(ﬁg. 4a).2
2. As described in the ﬁgure legend, our ﬁgure 5f shows
weak immunoreactivity of TAF1 in neurons in the patient’s
caudate and glial cells in both tissues but never implies
complete absence of TAF1 in the patient’s caudate.2
3. The possiblemechanism between the epigeneticmod-
iﬁcation and the reduced neuron-speciﬁc expression of the
TAF1, including the neuron-speciﬁc isoform that contains
exon 34′, which we discovered, were described in the “Dis-
cussion” section of our article.2
4. The postmortem brain was immediately frozen after
the patient’s death, so the point raised about our post-
mortem sample seems to be excessively speculative.2How-
ever, we are ready for a conﬁrmatory examination of other
frozen specimens, to give credence to our ﬁndings.
5. We hypothesize that neuronal death depends on dif-
ference of local conditions in various brain tissues—for
example, free radical production, calcium ﬂux, local tem-
perature, and dominant neurotransmitters, as illustrated
for dopamine receptor D2 (DRD2 [MIM *126450]) in ﬁgure
5c.2
For the family shown in the upper right of ﬁgure 3,2 the
picture scanned from the x-ray ﬁlm was accidentally mis-
aligned when the margin was trimmed. Our original x-ray
ﬁlm exactly shows the concordant signal with all other
patients, as described in our article.2 For the disease-spe-
ciﬁc SVA retrotransposon insertion, there is a striking dis-
crepancy between the results from of our work2 and the
work reported by Nolte et al.3 Nolte and colleagues stated
that they sequenced 260 kb of the critical interval in a
patient with XDP3; however, they did not ﬁnd the inser-
tion.We studied2 the patients with XDPwho had the same
STR/DSCs haplotype as that of the patients examined by
Nolte and colleagues.3 It might be argued that the element
was inserted only in the families we studied who carried
no etiological signiﬁcance in XDP. Nolte and colleagues
claimed that they determined the genomic sequence be-
yond 260 kb by “cycle sequencing of overlapping PCR
products,”3(p10347) without presenting any detailed infor-
mation about the experimental conditions and without
submitting their genomic sequence to any public data-
base. Such a mutation search analysis requires the com-
pleteness of the sequence to justify its conclusion in the
published work,3 so readers such as us might interpret the
sequence determined by Nolte and colleagues to be con-
tinuous and complete. It is, however, commonly believed
that it is extremely difﬁcult or almost impossible to de-
termine such a large genomic sequence with use of the
PCR-based sequence method, because of the complexity
of the human genome and the well-known technical lim-
itations, especially for long-range PCR. We ask Dr. Nolte
and colleagues to submit their completed sequence to a
public database, to strengthen the quality of their ﬁndings
and to enable any researcher interested in this ﬁeld to
compare with our complete sequence (DNA Database of
Japan accession number AB191243).
We hope that Dr. Mu¨ller and colleagues will succeed in
determining the complete and accurate structure and
abundance of MTS transcripts by means of various stan-
dard experiments, including northern blot, probe-hybrid-
ization screening of unbiased cDNA libraries, and TaqMan
assay, and then present a hypothesis about what leads to
the loss of striatal neurons by DSC3 on the MTS gene.
GEN TAMIYA, SATOSHI MAKINO, AND RYUJI KAJI
Web Resources
The accession number and URLs for data presented herein are
as follows:
DNA Database of Japan, http://www.ddbj.nig.ac.jp/Welcome-e
.html (for the complete genomic sequence of the DYT3 region
[accession number AB191243])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for XDP, TAF1, and DRD2)
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